Your session is about to expire
← Back to Search
Device
Prostate Cancer Imaging With Radioactive Tracer and Ultrasound Detector Compared to MRI and ProstaScint
Phase < 1
Waitlist Available
Led By Benjamin Franc, MD
Research Sponsored by Radiological Associates of Sacramento Medical Group Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within on month of scan and corresponding mri
Awards & highlights
No Placebo-Only Group
Summary
This is a small study to determine if probe, similar to an ultrasound probe, can detect prostate cancer more specifically than other imaging studies in patients with a positive prostate cancer biopsy.
Eligible Conditions
- Prostate Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ within on month of scan and corresponding mri
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within on month of scan and corresponding mri
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Detection of PSMA antibody (ProstaScint)uptake patterns measured by Proxiscan in comparison with anatomic biopsy reports, conventional SPECT and MRI scans within one month of Proxiscan
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Active Control
Group I: No interventionActive Control1 Intervention
All consenting patients will be imaged with the Proxiscan and data compared with MRI, ProstaScint and biopsy data
Find a Location
Who is running the clinical trial?
Hybridyne Imaging TechnologiesUNKNOWN
Radiological Associates of Sacramento Medical Group Inc.Lead Sponsor
Benjamin Franc, MDPrincipal InvestigatorRadiological Associates of Sacramento Medical Group Inc.